Elagolix, an oral GnRH antagonist, versus subcutaneous depot medroxyprogesterone acetate for the treatment of endometriosis: Effects on bone mineral density

Reproductive Sciences

Volumn 21, Issue 11, 2014, Pages 1341-1351

  Carr, Bruce ^a   Dmowski, W Paul ^b   O'Brien, Chris ^c   Jiang, Ping ^d   Burke, Joshua ^c   Jimenez, Roland ^c   Garner, Elizabeth ^d   Chwalisz, Kristof ^d  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b Institute for the Study and Treatment of Endometriosis   (United States)

^c NEUROCRINE BIOSCIENCES INC   (United States)

^d ABBVIE INC   (United States)

Author keywords

Elagolix; Endometriosis; GnRH antagonists; Pelvic pain

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; ELAGOLIX; ESTRADIOL; MEDROXYPROGESTERONE ACETATE; DELAYED RELEASE FORMULATION; FLUORINATED HYDROCARBON; GONADORELIN; HORMONE ANTAGONIST; MEDROXYPROGESTERONE; PYRIMIDINE DERIVATIVE;

ADULT; ARTICLE; BONE DENSITY; COMPOSITE PELVIC SIGN AND SYMPTOMS SCORE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DYSMENORRHEA; ENDOMETRIOSIS; FEMALE; FOLLOW UP; HEADACHE; HOT FLUSH; HUMAN; INTERACTIVE VOICE RESPONSE SYSTEM; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NAUSEA; PAIN ASSESSMENT; PELVIC PAIN; PHYSICAL DISEASE BY BODY FUNCTION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; UPPER RESPIRATORY TRACT INFECTION; UTERUS BLEEDING; VISUAL ANALOG SCALE; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; DELAYED RELEASE FORMULATION; DRUG EFFECTS; METABOLISM; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PAIN MEASUREMENT; PHASE 2 CLINICAL TRIAL; PHOTON ABSORPTIOMETRY; SUBCUTANEOUS DRUG ADMINISTRATION; TIME; TREATMENT OUTCOME; UNITED STATES;

ABSORPTIOMETRY, PHOTON; ADMINISTRATION, ORAL; ADULT; BONE DENSITY; DELAYED-ACTION PREPARATIONS; ENDOMETRIOSIS; FEMALE; GONADOTROPIN-RELEASING HORMONE; HORMONE ANTAGONISTS; HUMANS; HYDROCARBONS, FLUORINATED; INJECTIONS, SUBCUTANEOUS; MEDROXYPROGESTERONE; PAIN MEASUREMENT; PELVIC PAIN; PYRIMIDINES; TEXAS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84909589792     PISSN: 19337191     EISSN: 19337205     Source Type: Journal    
DOI: 10.1177/1933719114549848     Document Type: Article

References (25)

1. Carr BR. Endometriosis. In: Schorge JO, Schaffer JI, Halvorson LM, Hoffman B, Bradshaw KD, Cunningham FG, eds. Williams Gynecology. New York: McGraw-Hill; 2008:chapter 10.
2. Crosignani PG, Luciano A, Ray A, Bergqvist A. Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain. Hum Reprod (Oxford, England). 2006;21(1):248-256.
3. Schlaff WD, Carson SA, Luciano A, Ross D, Bergqvist A. Subcutaneous injection of depot medroxyprogesterone acetate compared with leuprolide acetate in the treatment of endometriosis-associated pain. Fertil Steril. 2006;85(2):314-325.
4. Vercellini P, Fedele L, Pietropaolo G, Frontino G, Somigliana E, Crosignani PG. Progestogens for endometriosis: forward to the past. Hum Reprod Update. 2003;9(4):387-396.
5. Batzer FR. GnRH analogs: options for endometriosis-associated pain treatment. J Minim Invasive Gynecol. 2006;13(6):539-545.
6. Olive DL. Gonadotropin-releasing hormone agonists for endometriosis. N Engl J Med. 2008;359(11):1136-1142.
7. Surrey ES. Gonadotropin-releasing hormone agonist and add-back therapy: what do the data show? Curr Opin Obstet Gynecol. 2010;22(4):283-288.
8. Struthers RS, Xie Q, Sullivan SK, et al. Pharmacological characterization of a novel nonpeptide antagonist of the human gonadotropin-releasing hormone receptor, NBI-42902. Endocrinology. 2007;148(2):857-867.
9. Struthers RS, Nicholls AJ, Grundy J, et al. Suppression of gonadotropins and estradiol in premenopausal women by oral administration of the nonpeptide gonadotropin-releasing hormone antagonist elagolix. J Clin Endocrinol Metab. 2009;94(2):545-551.
10. Kaunitz AM, Darney PD, Ross D, Wolter KD, Speroff L. Subcutaneous DMPA vs. intramuscular DMPA: a 2-year randomized study of contraceptive efficacy and bone mineral density. Contraception. 2009;80(1):7-17.
11. Berenson AB, Rahman M, Breitkopf CR, Bi LX. Effects of depot medroxyprogesterone acetate and 20-microgram oral contraceptives on bone mineral density. Obstet Gynecol. 2008;112(4):788-799.
12. Clark MK, Sowers M, Levy B, Nichols S. Bone mineral density loss and recovery during 48 months in first-time users of depot medroxyprogesterone acetate. Fertil Steril. 2006;86(5):1466-1474.
13. Shaarawy M, El-Mallah SY, Seoudi S, Hassan M, Mohsen IA. Effects of the long-term use of depot medroxyprogesterone acetate as hormonal contraceptive on bone mineral density and biochemical markers of bone remodeling. Contraception. 2006;74(4):297-302.
14. Kaunitz AM, Miller PD, Rice VM, Ross D, McClung MR. Bone mineral density in women aged 25-35 years receiving depot medroxyprogesterone acetate: recovery following discontinuation. Contraception. 2006;74(2):90-99.
15. Isley MM, Kaunitz AM. Update on hormonal contraception and bone density. Rev Endocr Metab Disord. 2011;12(2):93-106.
16. Biberoglu KO, Behrman SJ. Dosage aspects of danazol therapy in endometriosis: short-term and long-term effectiveness. Am J Obstet Gynecol. 1981;139(6):645-654.
17. Jones G, Jenkinson C, Kennedy S. Development of the short form endometriosis health profile questionnaire: the EHP-5. Qual Life Res. 2004;13(3):695-704.
18. Carr B, Chwalisz K, Jimenez R, Burke J, Jiang P, O'Brien C. A novel oral GnRH antagonist, elagolix, is effective for reducing endometriosis-associated pelvic pain: results of a 24-week randomized study. Fertil Steril. 2011;96(3):S45.
19. Imani R T-CD, Jimenez R, Burke J, Kroll R, O'Brien C. Petal study: safety, tolerability and effectiveness of elagolix, an oral GnRH antagonist for endometriosis. Fertil Steril. 2009;92(3):S111-S112.
20. Cosson M, Querleu D, Donnez J, et al. Dienogest is as effective as triptorelin in the treatment of endometriosis after laparoscopic surgery: results of a prospective, multicenter, randomized study. Fertil Steril. 2002;77(4):684-692.
21. Vercellini P, Cortesi I, Crosignani PG. Progestins for symptomatic endometriosis: a critical analysis of the evidence. Fertil Steril. 1997;68(3):393-401.
22. Overton CE, Lindsay PC, Johal B, et al. A randomized, doubleblind, placebo-controlled study of luteal phase dydrogesterone (Duphaston) in women with minimal to mild endometriosis. Fertil Steril. 1994;62(4):701-707.
23. Lockhat FB, Emembolu JO, Konje JC. The evaluation of the effectiveness of an intrauterine-administered progestogen (levonorgestrel) in the symptomatic treatment of endometriosis and in the staging of the disease. Hum Reprod. 2004;19(1):179-184.
24. Hornstein MD, Surrey ES, Weisberg GW, Casino LA. Leuprolide acetate depot and hormonal add-back in endometriosis: a 12-month study. Lupron Add-Back Study Group. Obstet Gynecol. 1998;91(1):16-24.
25. Friedman AJ, Hornstein MD.Gonadotropin-releasing hormone agonist plus estrogen-progestin "add-back" therapy for endometriosis-related pelvic pain. Fertil Steril. 1993;60(2):236-241.